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Abstract: A 51-year-old male was referred to the University Eye Clinic of Ioannina with 
nonarteritic anterior ischemic optic neuropathy (NAION) 12 hours after receiving sildenafil citrate 
(Viagra®). Examination for possible risk factors revealed mild hypercholesterolemia. Family 
history showed that his father had suffered from bilateral NAION. Although a cause-and-effect 
relationship is difficult to prove, there are reports indicating an association between the use of 
erectile dysfunction agents and the development of NAION. Physicians might need to investigate 
the presence of family history of NAION among systemic or vascular predisposing risk factors 
before prescribing erectile dysfunction drugs.
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Case report
A nonsmoker 51 year-old man used sildenafil citrate (Viagra®) for erectile dysfunction. 
The patient did not clarify the quantity of the drug that he used the previous day, but 
he mentioned during history recording that he had been using this specific agent for 
the last 6 months at least once a week. The patient did not receive any other treatments 
before this attack.
The following morning, he noted painless blurred vision in his right eye and he 
was referred to the University Eye Clinic of Ioannina. Ophthalmologic examination 
revealed a corrected visual acuity of 1/10 for the right eye and 10/10 for the left eye. 
Examination of the pupils showed a relative afferent pupillary defect of the right pupil. 
Biomicroscopy of the anterior segment did not show any pathological manifestations. 
Intraocular pressure was 12 mmHg for both eyes. The color vision score for the 
affected eye was 10 out of 15 Ishihara plates while the unaffected eye had a score of 
15 out of 15.
Dilated fundus examination revealed swelling of the right optic disk while the 
  vessels, macula, and the peripheral retina were normal. Goldmann perimetry showed 
superior visual field loss of the right eye. Fluoroangiography revealed hyperfluorescence 
of the right optic disk and leakage from it, indicating edema. The patient was not 
hyperopic and the cup-to-disk ratio in the fellow eye was 0.3.
Laboratory tests excluded diabetes, sarcoidosis, blood dyscrasias, and hypercoagu-
lable states. Syphilis screening tests, antinuclear antibodies, antinuclear cytoplasmic 
antibodies, and anticardiolipin antibody tests were all negative. In addition, laboratory 
screening revealed that erythrocyte sedimentation rate, C-reactive protein, and blood Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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count were in the normal range. There was, however, mild 
hypercholesterolemia (220 mg/dL). Chest radiography was 
normal. A magnetic resonance image scan of the brain and 
orbits with gadolinium demonstrated normal optic nerves and 
no white matter lesions. A Doppler ultrasound of the carotid 
arteries and neurological examination were also normal.
The above mentioned results led to the conclusion that 
the patient had experienced a NAION attack on his right eye. 
He was consulted to discontinue the use of sildenafil citrate. 
The patient was subjected to three subtenon injections of 
beta-methoxazone with a 20-day interval in between.
Visual acuity at the last follow-up evaluation, 1 year 
after the initial attack, improved to 8/10 for the right eye 
with ensued optic disk atrophy yet without any significant 
improvement concerning the impaired visual field.
Discussion
NAION is the most common acute optic neuropathy in 
older age groups with an estimated annual incidence of 
2.3 per 100,000.1,2 It is presumed to result from circulatory 
insufficiency within the optic nerve head, but the specific 
mechanism of the vasculopathy remains unproven. Therefore, 
the most important considerations in understanding the 
development of NAION are the factors that influence blood 
flow in the optic nerve head.
Hypovolemia, mainly due to severe surgical procedures,3,4 
atherosclerotic risk factors,5 hypercoagulable states,6–8 and 
crowded optic disk,9 in possible combination with regional 
vascular endothelial disorders has been implicated in the 
pathophysiology of NAION.
Over the last few years there has been an increasing 
  number of case reports concerning patients who have 
  developed NAION soon after the use of sildenafil and 
other phosphodiesterase type 5 inhibitors.10–13 It has been 
hypothesized that these agents might exaggerate the 
  physiologic nocturnal hypotension resulting in ischemia to 
the optic nerve head or that they might interfere with the 
autoregulation of blood flow thereby decreasing perfusion 
to the optic nerve head.14 In most of the reported cases of 
NAION after the use of sildenafil, patients detected visual 
loss upon awakening in the morning. It is usually described 
6–36 hours after use of the agent, as it was in this case.
The majority of affected users of phosphodiesterase 
type 5 inhibitors suffer already from other possible risk 
factors for NAION. In a retrospective matched case-control 
study, 38 patients with NAION and age-matched controls 
without previous history of NAION were questioned for the 
use of erectile dysfunction agents. The study showed that 
men with a history of myocardial infarction or hypertension 
are at increased risk for NAION when using sildenafil or 
taldenafil.15
In this case, the patient had mild hypercholesterolemia 
without any other systemic or vascular predisposing risk 
factors based on clinical examination and the rest of the 
screening as described above. However, the family history 
of his father having suffered from bilateral attacks of NAION 
indicates the possible presence of anatomical or other 
unidentified risk factors for the development of NAION.
The role of hereditary factors in familial NAION remains 
unknown and the only clinical difference between classical 
and familial NAION is that the familial type seems to have an 
earlier onset and a higher frequency of bilateral disease.16
This case might support all previous indications of 
the association between NAION and the use of erectile 
dysfunction drugs. Since it seems that sildenafil can 
  provoke NAION in some individuals who have a risk profile, 
the physician might need to investigate the presence of a 
family history of NAION among other risk factors before 
prescribing erectile dysfunction drugs.
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